Biocon Biologics gets credit boost from S&P, outlook stable
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
Pangea will use its integrated validation platform and regulatory expertise to oversee analytical and clinical validation of Gene Solutions’ multi-omics technologies.
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
Subscribe To Our Newsletter & Stay Updated